Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects M Ingelman-Sundberg, SC Sim, A Gomez, C Rodriguez-Antona Pharmacology & therapeutics 116 (3), 496-526, 2007 | 1528 | 2007 |
Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity M Ingelman-Sundberg The pharmacogenomics journal 5 (1), 6-13, 2005 | 1438 | 2005 |
Dietary long-chain n− 3 fatty acids for the prevention of cancer: a review of potential mechanisms SC Larsson, M Kumlin, M Ingelman-Sundberg, A Wolk The American journal of clinical nutrition 79 (6), 935-945, 2004 | 1276 | 2004 |
Metabolic gene polymorphism frequencies in control populations S Garte, L Gaspari, AK Alexandrie, C Ambrosone, H Autrup, JL Autrup, ... Cancer Epidemiology Biomarkers & Prevention 10 (12), 1239-1248, 2001 | 1145 | 2001 |
A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants SC Sim, C Risinger, ML Dahl, E Aklillu, M Christensen, L Bertilsson, ... Clinical Pharmacology & Therapeutics 79 (1), 103-113, 2006 | 966 | 2006 |
Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future M Ingelman-Sundberg Trends in pharmacological sciences 25 (4), 193-200, 2004 | 876 | 2004 |
Pharmacogenomics and individualized drug therapy M Eichelbaum, M Ingelman-Sundberg, WE Evans Annu. Rev. Med. 57 (1), 119-137, 2006 | 875 | 2006 |
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. I Johansson, E Lundqvist, L Bertilsson, ML Dahl, F Sjöqvist, ... Proceedings of the National Academy of Sciences 90 (24), 11825-11829, 1993 | 844 | 1993 |
Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment M Ingelman-Sundberg, M Oscarson, RA McLellan Trends in pharmacological sciences 20 (8), 342-349, 1999 | 816 | 1999 |
Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis MD Weltman, GC Farrell, P Hall, M Ingelman-Sundberg, C Liddle Hepatology 27 (1), 128-133, 1998 | 804 | 1998 |
Cytochrome P450 pharmacogenetics and cancer C Rodriguez-Antona, M Ingelman-Sundberg Oncogene 25 (11), 1679-1691, 2006 | 726 | 2006 |
Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease CC Bell, DFG Hendriks, SML Moro, E Ellis, J Walsh, A Renblom, ... Scientific reports 6 (1), 25187, 2016 | 698 | 2016 |
Perinatal morbidity and mortality in early‐onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE) C Lees, N Marlow, B Arabin, CM Bilardo, C Brezinka, JB Derks, J Duvekot, ... Ultrasound in obstetrics & gynecology 42 (4), 400-408, 2013 | 652 | 2013 |
Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P-450 (P-450IIE1) G Ekström, M Ingelman-Sundberg Biochemical pharmacology 38 (8), 1313-1319, 1989 | 649 | 1989 |
Nomenclature for human CYP2D6 alleles AK Daly, J Brockmoller, F Broly, M Eichelbaum, WE Evans, FJ Gonzalez, ... Pharmacogenetics and Genomics 6 (3), 193-201, 1996 | 610 | 1996 |
Worldwide distribution of cytochrome P450 alleles: a meta‐analysis of population‐scale sequencing projects Y Zhou, M Ingelman‐Sundberg, VM Lauschke Clinical Pharmacology & Therapeutics 102 (4), 688-700, 2017 | 592 | 2017 |
Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. I Johansson, M Oscarson, QY Yue, L Bertilsson, F Sjöqvist, ... Molecular pharmacology 46 (3), 452-459, 1994 | 588 | 1994 |
Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. E Aklillu, I Persson, L Bertilsson, I Johansson, F Rodrigues, ... Journal of pharmacology and experimental therapeutics 278 (1), 441-446, 1996 | 544 | 1996 |
Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms M Ingelman-Sundberg Naunyn-Schmiedeberg's archives of pharmacology 369, 89-104, 2004 | 504 | 2004 |
Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis. ML Dahl, I Johansson, L Bertilsson, M Ingelman-Sundberg, F Sjöqvist Journal of Pharmacology and Experimental Therapeutics 274 (1), 516-520, 1995 | 455 | 1995 |